Eupatilin Inhibits Renal Cancer Growth by Downregulating MicroRNA-21 through the Activation of YAP1
Figure 1
Effect of Eupatilin on proliferation, apoptosis, and migration of renal cell carcinoma in vitro. (a) The molecular structure of Eupatilin. (b) 786-O cells were treated with Eupatilin (5, 10, or 20 mM) for 24 h. Cell viability was detected with the CCK8 assay. Data are expressed as the mean ± SEM (n = 3) of three independent experiments. (P < 0.01 versus control). (c) 786-O cells were treated with Eupatilin (5, 10, or 20 mM) for 24 h. The apoptosis of 786-O cells was detected by flow cytometry. (d) Quantification of the results of (c). Data are expressed as the mean ± SEM (n = 3) of three independent experiments. (P < 0.05 and P < 0.01 versus control). (e) 786-O cells were treated with Eupatilin (5, 10, or 20 mM) for 24 h. The migration ability of 786-O cells was detected with the Transwell assay. (f) Quantification of the results in (e). Data are expressed as the mean ± SEM (n = 3) of three independent experiments. (P < 0.001 versus control).